“Fresh Perspectives” is on display through Feb. 23 at Lemon Street. Prizes will be awarded during the opening reception, 6-9 p.m. Saturday, Feb. 8. The reception is free, and everyone is welcom ...

DALLAS, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView ® System, which received Breakthrough Device Designation from ...

After just a few years on the market, a new wave of GLP-1 drugs approved for weight loss have upended what we know about obesity. By now, these are household names: Mounjaro. Wegovy. Zepbound ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

BUFFALO, N.Y. — A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a direct causal link with the drugs has not been established.

Busà Photography / Getty Images Many people believe that being wealthy means having a nice house, a late-model car, and a summer cottage, but the kind of money possessed by the wealthiest 1% of ...

Josh Gad is opening up about the weight loss success he’s had with GLP-1 medication — and sharing some of the conflicted feelings he’s had along the way. “I’m on a GLP-1 … this is the ...

Unfortunately, many patients may choose to forego additional treatments due to the dramatic increase in cost associated with brand name versus compounded GLP-1 drugs. 5. Q. Are any GLP-1s still on ...

In a meta-analysis of nine randomized controlled trials, adults had an average lean mass loss of 2.5 kg with GLP-1 therapy. More research is needed to examine the implications of lean mass loss ...

The risks for disease progression and death were lower for patients with stage 3b or higher CKD receiving GLP-1 RA vs DPP4i. Real-world data show that treatment with glucagon-like peptide-1 ...

HealthDay News — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online Jan. 16 ...

“Our study confirms the increased likelihood of being diagnosed with what appears to be low-risk thyroid cancer after treatment with GLP-1 RAs — but not because patients treated with GLP-1 RAs ...